Next Article in Journal
Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition
Next Article in Special Issue
Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future
Previous Article in Journal
Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2015, 8(3), 607-636; doi:10.3390/ph8030607

Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy

Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7305, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Luciano J. Costa
Received: 14 August 2015 / Revised: 2 September 2015 / Accepted: 7 September 2015 / Published: 17 September 2015
(This article belongs to the Special Issue New Drugs in Hematology)
View Full-Text   |   Download PDF [407 KB, uploaded 17 September 2015]   |  

Abstract

There has been a recent emergence of novel targeted agents for treatment of Hodgkin and non-Hodgkin lymphoma. In particular, antibodies and antibody-drug conjugates directed against surface antigens, agents that block immune checkpoint pathways, and small molecule inhibitors directed against cell signaling pathways have shown significant promise in patients with relapsed and refractory disease and in the frontline setting. With the development of these new therapies, cytotoxic chemotherapy may be avoided entirely in some clinical settings. This review will present the latest information on these novel treatments in Hodgkin and non-Hodgkin lymphoma and will discuss both recently approved agents as well as drugs currently being studied in clinical trials. View Full-Text
Keywords: Hodgkin lymphoma; non-Hodgkin lymphoma; monoclonal antibody; antibody-drug conjugates; immune-checkpoint inhibitors; small molecule inhibitors Hodgkin lymphoma; non-Hodgkin lymphoma; monoclonal antibody; antibody-drug conjugates; immune-checkpoint inhibitors; small molecule inhibitors
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Grover, N.S.; Park, S.I. Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy. Pharmaceuticals 2015, 8, 607-636.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top